FluoGuide A/S (FLUO.ST)
SEK 37.0
(-1.99%)
SEK 37.0
(-1.99%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -3.22 DKK | -38.2% |
| 2022 | -2.33 DKK | -8.37% |
| 2021 | -2.15 DKK | -20.79% |
| 2020 | -1.78 DKK | -19.46% |
| 2019 | -1.49 DKK | -1640.65% |
| 2018 | -0.09 DKK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.59 DKK | 4.84% |
| 2024 Q1 | -0.62 DKK | 39.22% |
| 2023 Q3 | -0.78 DKK | -30.0% |
| 2023 FY | - DKK | -38.2% |
| 2023 Q4 | -1.02 DKK | -30.77% |
| 2023 Q2 | -0.60 DKK | 25.93% |
| 2023 Q1 | -0.81 DKK | 10.0% |
| 2022 FY | - DKK | -8.37% |
| 2022 Q3 | -0.60 DKK | -20.0% |
| 2022 Q2 | -0.50 DKK | -42.86% |
| 2022 Q1 | -0.35 DKK | 50.0% |
| 2022 Q4 | -0.90 DKK | -50.0% |
| 2021 Q3 | -0.71 DKK | -77.5% |
| 2021 Q2 | -0.40 DKK | -25.0% |
| 2021 Q1 | -0.32 DKK | 48.39% |
| 2021 FY | - DKK | -20.79% |
| 2021 Q4 | -0.70 DKK | 1.41% |
| 2020 FY | - DKK | -19.46% |
| 2020 Q4 | -0.62 DKK | -181.82% |
| 2020 Q3 | -0.22 DKK | 60.0% |
| 2020 Q2 | -0.55 DKK | -44.74% |
| 2020 Q1 | -0.38 DKK | 11.63% |
| 2019 Q4 | -0.43 DKK | 23.21% |
| 2019 Q3 | -0.56 DKK | -143.48% |
| 2019 Q2 | -0.23 DKK | 37.84% |
| 2019 Q1 | -0.37 DKK | -1435.27% |
| 2019 FY | - DKK | -1640.65% |
| 2018 Q4 | -0.02 DKK | 0.0% |
| 2018 Q3 | - DKK | 0.0% |
| 2018 FY | - DKK | 0.0% |
| 2018 Q2 | - DKK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AddLife AB (publ) | 1.56 SEK | 306.41% |
| Biotage AB (publ) | 3.33 SEK | 196.697% |
| Bonesupport Holding AB (publ) | 3.77 SEK | 185.411% |
| Doxa AB (publ) | 0.60 SEK | 636.667% |
| Elekta AB (publ) | 3.41 SEK | 194.428% |
| iZafe Group AB (publ) | -0.14 SEK | -2200.0% |
| Ortivus AB (publ) | -0.41 SEK | -685.366% |
| Ortivus AB (publ) | -0.41 SEK | -685.366% |
| Q-linea AB (publ) | -3.48 SEK | 7.471% |
| S2Medical AB (publ) | -0.14 SEK | -2200.0% |
| Synsam AB (publ) | 2.09 SEK | 254.067% |